Gilead Must Pay Merck $200 Million for Hepatitis C Patents

  • Merck demanded royalty saying it paved way for liver remedy
  • Gilead failed to convince jury Merck drug patents are invalid

Gilead Sciences Inc. was ordered by a jury to pay Merck & Co. $200 million for patent infringement over a drug compound that cures hepatitis C, a tenth of what Merck sought.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.